DOCSLIB.ORG

Leu124serfs*26, a Novel AGPAT2 Mutation in Congenital Generalized Lipodystrophy with Early Cardiovascular Complications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Leu124serfs*26, a Novel AGPAT2 Mutation in Congenital Generalized Lipodystrophy with Early Cardiovascular Complications Montenegro Junior et al. Diabetol Metab Syndr (2020) 12:28 Diabetology & https://doi.org/10.1186/s13098-020-00538-y Metabolic Syndrome RESEARCH Open Access Leu124Serfs*26, a novel AGPAT2 mutation in congenital generalized lipodystrophy with early cardiovascular complications Renan Magalhães Montenegro Junior1* , Grayce Ellen da Cruz Paiva Lima1, Virgínia Oliveira Fernandes1, Ana Paula Dias Rangel Montenegro1, Clarisse Mourão Melo Ponte1, Lívia Vasconcelos Martins1, Daniel Pascoalino Pinheiro2, Maria Elisabete Amaral de Moraes2, Manoel Odorico de Moraes Filho2 and Catarina Brasil d’Alva1 Abstract Background: Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by the near-total loss of subcutaneous adipose tissue soon after birth, resulting in ectopic fat deposition and severe meta- bolic disturbances. Most cases are caused by AGPAT2 or BSCL2 gene mutations. We aimed to report two unrelated CGL patients with a novel frameshift mutation in AGPAT2 (p.Leu124Serfs*26). Methods: Clinical features and laboratory were obtained by medical interview and medical records review. DNA was extracted, amplifed and sequenced. Mutation Taster was used to estimate the potential biological impact of the AGPAT2 mutations on the protein function. Results: Patient 1: a 30-year-old woman with lipodystrophy phenotype at birth and diagnosis of diabetes at age 13 presented with severe hypertriglyceridemia and pancreatitis at age 17, hypertension and albuminuria at age 18, prolif- erative diabetic retinopathy with visual loss at age 25, and an acute myocardial infarction due to multivessel coronary disease during a hospitalization for forefoot amputation at age 29. At this time, she required hemodialysis due to end- stage renal disease. Patient 2: a 12-year-old girl with lipodystrophy phenotype and hypertriglyceridemia detected in the frst year of life and abnormalities in the global longitudinal strain, evaluated by speckle-tracking echocardiogra- phy last year. Molecular analysis identifed a c.369_372delGCTC (p.Leu124Serfs*26) AGPAT2 mutation in both unrelated patients, a compound heterozygous mutation in Patient 1, and homozygous mutation in Patient 2. Conclusion: We describe two unrelated patients with type 1 CGL due to Leu124Serfs*26, a novel AGPAT2 frameshift mutation, presenting as early cardiovascular disease. These fndings suggest an association between Leu124Serfs*26 and a more aggressive phenotype. Keywords: Congenital generalized lipodystrophy, AGPAT2, Cardiovascular disease Background Congenital generalized lipodystrophy (CGL; OMIN 608594) is a rare autosomal recessive disorder charac- *Correspondence: [email protected] terized by the total or near-total loss of subcutaneous 1 Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Faculdade de Medicina, Universidade Federal do Ceará, Rua adipose tissue soon after birth, resulting in ectopic fat Professor Costa Mendes, 1608, Rodolfo Teóflo, Fortaleza, Ceará 60416200, deposition and metabolic complications. Tese patients Brazil present severe insulin resistance (IR), diabetes mellitus, Full list of author information is available at the end of the article © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Montenegro Junior et al. Diabetol Metab Syndr (2020) 12:28 Page 2 of 9 hypertriglyceridemia, hepatic steatosis, and cardiovascu- Blood glucose, cholesterol, and triglyceride levels lar disease [1–3]. were obtained after overnight fast and determined CGL is classifed into four subtypes—1, 2, 3, and 4— according to standard methods using automated equip- according to the afected gene, AGPAT2, BSCL2, CAV-1, ment. Glycohemoglobin A1c values were determined and CAVIN1, respectively. Most cases (95%) are subtypes by ion exchange high-performance liquid chromatog- 1 (CGL1) or 2 (CGL2). AGPAT2 is located in chromo- raphy (HPLC), and serum insulin levels were measured some 9q34 and encompasses six exons [4]. Tis gene by immunoassays with reagents provided by Roche codes a homonymous protein (1-acylglycerol-3-phos- Diagnostics (Basel, Switzerland). Tyroid stimulat- phate acyltransferase-β) that triggers the synthesis of ing hormone (TSH) and thyroid hormones (fT4 and triglycerides inside the adipocyte, converting lysophos- T3) were measured using chemiluminescence (ADVIA phatidic acid to phosphatidic acid [5, 6]. Tis mutation Centaur® XP, Siemens). Plasma leptin levels were meas- infuences the peroxisome proliferator-activated receptor ured by an immunoassay using a commercial kit (DIA- gamma (PPARγ), the main regulator of adipocyte difer- source ImmunoAssays, Louvain-la-Neuve, Belgium). entiation [7–9]. HOMA–IR (homeostasis model assessment) was also Diferent AGPAT2 mutations have been described calculated (fasting glycaemia (mmol/L) × fasting insu- worldwide. Tis gene is expressed in various tissues, lin (μU/mL))÷22.5) [11]. including the gastrointestinal tract, heart, kidney, and Standard in-house protocols based on a salting-out liver, among others [10]. Descriptions of the clinical method were used to extract genomic DNA from periph- characteristics of patients carrying new mutations are eral blood leucocytes [12]. Te entire coding regions important since they may improve our understanding of and intron–exon junctions of AGPAT2 and BSCL2 were multiorgan diseases and adipose tissue physiology, and amplifed by polymerase chain reactions (PCR) using spe- this understanding may enable us to speculate about gen- cifc primers and were automatically sequenced; primer otype–phenotype associations. sequences are listed in Table 1. Amplifcation reactions In this study, we reported two unrelated CGL1 were executed in a fnal volume of 25 µL, comprising patients with a novel frameshift mutation in AGPAT2, 200 ng genomic DNA, 0.2 mM dNTPs, 1.5 mM PCR x NM_006412:p.Leu124Serfs*26. Enhancer Solution (Invitrogen), 0.6 pmol of each primer, ® 1× PCR bufer, and 1U GoTaq DNA polymerase (Pro- Methods mega, Madison, WI), and were executed for 35 cycles: Clinical features and laboratory and molecular data from denaturation at 95 °C for 30 s, annealing at 55–62 °C for two Brazilian patients from the state of Ceará, Northeast 30 s, extension at 72 °C for 1 min, and a fnal extension Brazil (Fig. 1), were obtained by medical interview and for 10 min at 72 °C. Te PCR products were checked on medical records review. 1% agarose gel electrophoresis, purifed, and automati- cally sequenced in an ABI PRISM™ 3100 Genetic Ana- lyzer automatic DNA sequencer (Applied Biosystems, Foster City, CA). All sequence variations were assessed on both strands and repeated in a second PCR. Table 1 Oligonucleotides used for AGPAT2 amplifcation and sequencing Primer AGPAT2-1F 5′-cgcaataaggggcctgag-3′ AGPAT2-1R 5′-ggaccccctcctgtgc-3′ AGPAT2-2F 5′-gggactctgtccgcttca-3′ AGPAT2-2R 5′-cagccctgtgtcctcgtc-3′ AGPAT2-3F 5′-ggtgctcagcagctgtcttc-3′ AGPAT2-3R 5′-tttctgccaaaaccaagtcac-3′ AGPAT2-4F 5′-aaaacaagacccccacatcat-3′ AGPAT2-4R 5′-gaggagtcccttgtgtgtcaag-3′ AGPAT2-5F 5′-cctcagctgtgcgtctcc-3′ AGPAT2-5R 5′-gagtcactcattcgccacat-3′ AGPAT2-6F 5′-ctagggagtccaggggaaga-3′ Fig. 1 CGL pa–tients’ hometowns (in red) in the state of Ceará, Brazil AGPAT2-6R 5′-agtgacagaaggggcttcct-3′ Montenegro Junior et al. Diabetol Metab Syndr (2020) 12:28 Page 3 of 9 Mutation Taster was used to estimate the potential Results biological impact of the AGPAT2 mutations on the Study subjects protein function. This is a web-based application that Patient 1 performs a battery of in silico tests on protein and Patient 1 was a 30-year-old woman (Fig. 2), non-smoker, DNA level to estimate the impact of a variant on the born full-term (unknown birth weight) as the third child gene product. It predicts the functional consequences of nonconsanguineous parents in the city of Cascavel, of amino acid substitutions as well as intronic and state of Ceará, Brazil (Fig. 1). Lipodystrophic phenotype synonymous alterations, short insertion and deletion was detected at birth and the diagnosis of CGL was given mutations, and variants spanning intro-exon borders. at the age of 6 months when she was hospitalized due to a The program filter harmless mutations from the dis- respiratory infection. Hypertriglyceridemia (223 mg/dL) ease-causing ones by comparison with integrated data- was also detected at that time. bases and perform tests to determine the nature of the She had no clinical follow-up until the age 13, when given variant, that comprises the amino acid substitu- she was diagnosed with diabetes mellitus and,
Load more

Recommended publications
  • AGPAT2 Gene 1-Acylglycerol-3-Phosphate O-Acyltransferase 2
    AGPAT2 gene 1-acylglycerol-3-phosphate O-acyltransferase 2 Normal Function The AGPAT2 gene provides instructions for making an enzyme that is found in many of the body's cells and tissues. It plays a critical role in the growth and development of adipocytes, which are cells that store fats for energy. Adipocytes are the major component of the body's fatty (adipose) tissue. The AGPAT2 enzyme is part of a chemical pathway in many cells that produces two important types of fats (lipids): glycerophospholipids and triacylglycerols. Glycerophospholipids are the major component of cell membranes and are involved in chemical signaling within cells. Triacylglycerols (also known as triglycerides) are fat molecules that are stored in adipocytes for later conversion to energy. The AGPAT2 enzyme is responsible for a particular chemical reaction in the production of these two types of lipids. Specifically, the enzyme helps convert a molecule called lysophosphatidic acid (LPA) to another molecule, phosphatidic acid (PA). Additional reactions convert phosphatidic acid to glycerophospholipids and triacylglycerols. Health Conditions Related to Genetic Changes Congenital generalized lipodystrophy At least 26 mutations in the AGPAT2 gene have been identified in people with congenital generalized lipodystrophy (also called Berardinelli-Seip congenital lipodystrophy) type 1. This rare condition is characterized by an almost total absence of adipose tissue and a very muscular appearance. A shortage of adipose tissue leads to multiple health problems, including high levels of triglycerides circulating in the bloodstream (hypertriglyceridemia) and diabetes mellitus. The AGPAT2 gene mutations that cause congenital generalized lipodystrophy type 1 greatly reduce or eliminate the activity of the AGPAT2 enzyme.
    [Show full text]
  • Biomolecules
    biomolecules Article The Vitamin D Receptor Regulates Glycerolipid and Phospholipid Metabolism in Human Hepatocytes Teresa Martínez-Sena 1, Polina Soluyanova 1, Carla Guzmán 1, José Manuel Valdivielso 2 , José Vicente Castell 1,3,4 and Ramiro Jover 1,3,4,* 1 Experimental Hepatology Unit, IIS Hospital La Fe, 46026 Valencia, Spain; [email protected] (T.M.-S.); [email protected] (P.S.); [email protected] (C.G.); [email protected] (J.V.C.) 2 Vascular and Renal Translational Research Group, Experimental Medicine Department, IRBLleida, 25196 Lleida, Spain; [email protected] 3 Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain 4 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), ISCIII, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-96124-6653 Received: 21 February 2020; Accepted: 20 March 2020; Published: 24 March 2020 Abstract: The vitamin D receptor (VDR) must be relevant to liver lipid metabolism because VDR deficient mice are protected from hepatosteatosis. Therefore, our objective was to define the role of VDR on the overall lipid metabolism in human hepatocytes. We developed an adenoviral vector for human VDR and performed transcriptomic and metabolomic analyses of cultured human hepatocytes upon VDR activation by vitamin D (VitD). Twenty percent of the VDR responsive genes were related to lipid metabolism, including MOGAT1, LPGAT1, AGPAT2, and DGAT1 (glycerolipid metabolism); CDS1, PCTP, and MAT1A (phospholipid metabolism); and FATP2, SLC6A12, and AQP3 (uptake of fatty acids, betaine, and glycerol, respectively). They were rapidly induced (4–6 h) upon VDR activation by 10 nM VitD or 100 µM lithocholic acid (LCA).
    [Show full text]
  • Supplemental Table 1. List of Candidate Gene Filters Used in the Analysis of Exome Sequencing. MYOPATHY NEUROPATHY MND ABHD5
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Supplemental table 1. List of candidate gene filters used in the analysis of exome sequencing. MYOPATHY NEUROPATHY MND ABHD5 AAAS AAAS ACADL AARS1 AARS1 ACADM ABCA1 AGT ACADS ABCD1 ALAD ACADVL ABHD12 ALS2 ACTA1 ADCY6 ANG ADSSL1 AFG3L2 APEX1 AGL AIFM1 APOE AGPAT2 AMACR AR AGRN ANG ASAH1 AIRE AP1S1 ATM ALDOA APOA1 ATP7A ALG14 APTX ATXN2 ALG2 ARHGEF10 ATXN3 ALG3 ARL6IP1 B4GALT6 ANKRD2 ARSA BCL11B ANO5 ASAH1 BCL6 ASCC1 ATL1 BICD2 ATGL ATL3 BSCL2 ATP2A1 ATM C19orf12 ATRN ATXN1 C9orf72 B3GALNT2 ATXN10 CCS B3GNT2 ATXN2 CDH13 BAG3 ATXN3 CDH22 BIN1 ATXN7 CHCHD10 BSCL2 B2M CHMP2B BVES B4GALNT1 CNTF CACNA1S BAG3 CNTN4 CAPN3 BCKDHB CNTN6 CASQ1 BSCL2 CRIM1 CAV1 C12orf65 CRYM CAV3 C9orf72 CSNK1G3 CAVIN1 CLP1 CST3 CCDC78 CNTNAP1 CUL4B CDKN1C COX10 CYP2D6 CFL2 COX6A1 DAO Grunseich C, et al. J Neurol Neurosurg Psychiatry 2021;0:1–11. doi: 10.1136/jnnp-2020-325437 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry CHAT CPOX DCAF15 CHCHD10 CRYAB DCTN1 CHD7 CTDP1 DIAPH3 CHKB CTSA DISC1 CHN1 CYP27A1 DNAJB2 CHRM3 DARS2 DOC2B CHRNA1 DDHD1 DPP6 CHRNB1 DGUOK DYNC1H1 CHRND DHH EFEMP1 CHRNE DHTKD1 ELP3 CIDEC DMD EPHA4 CLCN1 DNAJB2 EWSR1 CLN3 DNAJC3 EXOSC3 CNBP DNM2 FBLN5 CNTN1 DYNC1H1 FBXO38 COA3 EGR2 FEZF2 COL12A1 EMD FGGY COL13A1 ERCC6 FIG4 COL6A ERCC8 FUS COL6A1 FAH GARS1 COL6A2 FAM126A GBE1 COL6A3 FBLN5 GMPPA COL9A3 FGD4 GRB14 COLQ FGF14 GRN COX10 FIG4 HEXA COX15 FLNC HFE CPT2 FLRT1 HINT1 CRAT FLVCR1 HSPB1 CRPPA FMR1 HSPB3 CRYAB FUS HSPB8 CTNS FXN IGHMBP2 DAG1 GALC ITPR2 DECR1 GAN KDR DES GARS1 KIFAP3 DGUOK GBA2 KLHL9 DIH1 GBE1 LAMA2 DMD GDAP1 LAS1L DMPK GJB1 LIF DNAJB6 GJB3 LIPC DNAJC19 GLA LOX Grunseich C, et al.
    [Show full text]
  • An Oxysterol Sensor and a Major Playerin the Control of Lipogenesis Simon Ducheix, J.M.A
    Liver X Receptor: an oxysterol sensor and a major playerin the control of lipogenesis Simon Ducheix, J.M.A. Lobaccaro, Pascal G.P. Martin, Hervé Guillou To cite this version: Simon Ducheix, J.M.A. Lobaccaro, Pascal G.P. Martin, Hervé Guillou. Liver X Receptor: an oxysterol sensor and a major playerin the control of lipogenesis. Chemistry and Physics of Lipids, Elsevier, 2011, 164 (6), pp.500-14. 10.1016/j.chemphyslip.2011.06.004. hal-02651993 HAL Id: hal-02651993 https://hal.inrae.fr/hal-02651993 Submitted on 29 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Chemistry and Physics of Lipids 164 (2011) 500–514 Contents lists available at ScienceDirect Chemistry and Physics of Lipids journal homepage: www.elsevier.com/locate/chemphyslip Review Liver X Receptor: an oxysterol sensor and a major player in the control of lipogenesis S. Ducheix a, J.M.A. Lobaccaro b, P.G. Martin a, H. Guillou a,∗ a Integrative Toxicology and Metabolism, UR 66, ToxAlim, INRA, 31 027 Toulouse Cedex 3, France b Clermont Université, CNRS Unité Mixte de Recherche 6247 Génétique, Reproduction et Développement, Université Blaise Pascal, Centre de Recherche en Nutrition Humaine d’Auvergne, BP 10448, F-63000 Clermont-Ferrand, France article info abstract Article history: De novo fatty acid biosynthesis is also called lipogenesis.
    [Show full text]
  • Transcriptional Regulation Profiling Reveals Disrupted Lipid Metabolism in Failing Hearts with a Pathogenic Phospholamban Mutation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.402792; this version posted December 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Transcriptional regulation profiling reveals disrupted lipid metabolism in failing hearts with a pathogenic phospholamban mutation Jiayi Pei1,2,3*, Renee G.C. Maas1,2*, Ema Nagyova1,4, Johannes M.I.H. Gho1, Christian Snijders Blok1,2, Iris van Adrichem1,2, Jorg J.A. Calis1,2, René van Es1, Shahrzad Sepehrkhouy5, Dries Feyen6, Noortje van den Dungen4, Nico Lansu4, Nicolaas de Jonge1, Hester M. den Ruijter1, Manon M.H. Huibers5, Roel A. de Weger5, Linda W. van Laake1, Marianne C. Verhaar2,3, Peter van Tintelen7, Frank G. van Steenbeek1,2,8, Alain van Mil1,2, Jan W. Buikema1,2, Boudewijn Burgering9, Ioannis Kararikes6, Mark Mercola6, Pieter A. Doevendans1,10, Joost Sluijter1,2, Aryan Vink5, Caroline Cheng2,3, Michal Mokry2,4,11*, Folkert W. Asselbergs1,9,12,13*#, Magdalena Harakalova1,2*# *equal contribution; #corresponding authors 1 Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands 2 Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands 3 Department of Nephrology and Hypertension, Division of Internal Medicine and Dermatology, University Medical Center Utrecht (UMCU), The Netherlands 4 Epigenomics facility, University Medical Center Utrecht, Utrecht, The
    [Show full text]
  • Complete Account of the Selection Process
    Complete account of the selection process Andreas Hoppe. October 17, 2012 Contents 1 Principles 1 1.1 Selection of functions . 1 1.2 Selection of genes . 2 2 Selection in detail 3 2.1 Collagens . 4 2.2 Ethanol degradation . 5 2.3 Sphinganine-1P synthesis . 6 2.4 Tyrosine degradation . 7 2.5 Panthetheine synthesis . 8 2.6 Inositol synthesis . 9 2.7 Urea synthesis . 9 2.8 Bilirubin conjugation . 10 2.9 Cholesterol synthesis . 10 2.10 Bile acid synthesis and excretion . 12 2.11 b-hydroxybutyrate . 13 2.12 Glycolysis . 13 2.13 Triglycerides . 14 1 Principles 1.1 Selection of functions The selection process was based on the result of the ModeScore computation of the most regulated metabolic functions, in particular (with decreasing order of importance) • the comparison of the control and the TGFb series at the 24h time point (C/T 24h), • the comparison of the 1h to the 24h time point in the control series (C1h/24h), • the comparison of the 1h to the 24h time point in the TGFb series (T1h/24h), • the comparison of the 1h to the 6h time point in the control series (C1h/6h) in conjunction with the comparison of the 6h to the 24h time point in the control series (C6h/24h), and • the comparison of the control and the TGFb series at the 6h time point (C/T 6h), • the comparison of the 1h to the 6h time point in the control series (T1h/24h) in conjunction with the comparison of the 6h to the 24h time point in the TGFb series (T6h/24h) — not shown in the diagrams below.
    [Show full text]
  • Inheritest 500 PLUS
    Inheritest® 500 PLUS 525 genes Specimen ID: 00000000010 Container ID: H0651 Control ID: Acct #: LCA-BN Phone: SAMPLE REPORT, F-630049 Patient Details Specimen Details Physician Details DOB: 01/01/1991 Date Collected: 08/05/2019 12:00 (Local) Ordering: Age (yyy/mm/dd): 028/07/04 Date Received: 08/06/2019 Referring: Gender: Female Date Entered: 08/06/2019 ID: Patient ID: 00000000010 Date Reported: 08/21/2019 15:29 (Local) NPI: Ethnicity: Unknown Specimen Type: Blood Lab ID: MNEGA Indication: Carrier screening Genetic Counselor: None SUMMARY: POSITIVE POSITIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Spinal muscular atrophy AT RISK AT RISK to be a silent carrier (2+0). For ethnic-specific risk (SMN1) 2 copies of SMN1; positive for revisions see Methods/Limitations. Genetic counseling is NMID: NM_000344 c.*3+80T>G SNP recommended. Risk: AT INCREASED RISK FOR AFFECTED PREGNANCY. See Additional Clinical Information. NEGATIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Cystic fibrosis NEGATIVE This result reduces, but does not eliminate the risk to be a (CFTR) carrier. NMID: NM_000492 Risk: NOT at an increased risk for an affected pregnancy. Fragile X syndrome NEGATIVE: Not a carrier of a fragile X expansion. (FMR1) 29 and 36 repeats NMID: NM_002024 Risk: NOT at an increased risk for an affected pregnancy. ALL OTHER DISORDERS NEGATIVE This result reduces, but does not eliminate the risk to be a carrier. Risk: The individual is NOT at an increased risk for having a pregnancy that is affected with one of the disorders covered by this test. For partner's gene-specific risks, visit www.integratedgenetics.com.
    [Show full text]
  • Downregulation of Carnitine Acyl-Carnitine Translocase by Mirnas
    Page 1 of 288 Diabetes 1 Downregulation of Carnitine acyl-carnitine translocase by miRNAs 132 and 212 amplifies glucose-stimulated insulin secretion Mufaddal S. Soni1, Mary E. Rabaglia1, Sushant Bhatnagar1, Jin Shang2, Olga Ilkayeva3, Randall Mynatt4, Yun-Ping Zhou2, Eric E. Schadt6, Nancy A.Thornberry2, Deborah M. Muoio5, Mark P. Keller1 and Alan D. Attie1 From the 1Department of Biochemistry, University of Wisconsin, Madison, Wisconsin; 2Department of Metabolic Disorders-Diabetes, Merck Research Laboratories, Rahway, New Jersey; 3Sarah W. Stedman Nutrition and Metabolism Center, Duke Institute of Molecular Physiology, 5Departments of Medicine and Pharmacology and Cancer Biology, Durham, North Carolina. 4Pennington Biomedical Research Center, Louisiana State University system, Baton Rouge, Louisiana; 6Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine, New York, New York. Corresponding author Alan D. Attie, 543A Biochemistry Addition, 433 Babcock Drive, Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, (608) 262-1372 (Ph), (608) 263-9608 (fax), [email protected]. Running Title: Fatty acyl-carnitines enhance insulin secretion Abstract word count: 163 Main text Word count: 3960 Number of tables: 0 Number of figures: 5 Diabetes Publish Ahead of Print, published online June 26, 2014 Diabetes Page 2 of 288 2 ABSTRACT We previously demonstrated that micro-RNAs 132 and 212 are differentially upregulated in response to obesity in two mouse strains that differ in their susceptibility to obesity-induced diabetes. Here we show the overexpression of micro-RNAs 132 and 212 enhances insulin secretion (IS) in response to glucose and other secretagogues including non-fuel stimuli. We determined that carnitine acyl-carnitine translocase (CACT, Slc25a20) is a direct target of these miRNAs.
    [Show full text]
  • Macrophage ABHD5 Promotes Colorectal Cancer Growth by Suppressing Spermidine Production by SRM
    ARTICLE Received 17 Feb 2016 | Accepted 22 Apr 2016 | Published 18 May 2016 DOI: 10.1038/ncomms11716 OPEN Macrophage ABHD5 promotes colorectal cancer growth by suppressing spermidine production by SRM Hongming Miao1,*, Juanjuan Ou1,*, Yuan Peng1,*, Xuan Zhang1, Yujuan Chen1, Lijun Hao1, Ganfeng Xie1, Zhe Wang1, Xueli Pang1, Zhihua Ruan1, Jianjun Li1, Liqing Yu2, Bingzhong Xue3, Hang Shi3, Chunmeng Shi4 & Houjie Liang1 Metabolic reprogramming in stromal cells plays an essential role in regulating tumour growth. The metabolic activities of tumour-associated macrophages (TAMs) in colorectal cancer (CRC) are incompletely characterized. Here, we identify TAM-derived factors and their roles in the development of CRC. We demonstrate that ABHD5, a lipolytic co-activator, is ectopically expressed in CRC-associated macrophages. We demonstrate in vitro and in mouse models that macrophage ABHD5 potentiates growth of CRC cells. Mechanistically, ABHD5 suppresses spermidine synthase (SRM)-dependent spermidine production in macrophages by inhibiting the reactive oxygen species-dependent expression of C/EBPe, which activates transcription of the srm gene. Notably, macrophage-specific ABHD5 transgene-induced CRC growth in mice can be prevented by an additional SRM transgene in macrophages. Altogether, our results show that the lipolytic factor ABHD5 suppresses SRM-dependent spermidine production in TAMs and potentiates the growth of CRC. The ABHD5/SRM/spermidine axis in TAMs might represent a potential target for therapy. 1 Department of Oncology, Southwest Hospital, The Third Military Medical University, Chongqing 400038, China. 2 Department of Animal and Avian Sciences, University of Maryland, College Park, Maryland 20742, USA. 3 Department of Biology, Georgia State University, Atlanta, Georgia 30303, USA.
    [Show full text]
  • Adipocyte-Specific Deficiency of De Novo Sphingolipid Biosynthesis Leads to Lipodystrophy and Insulin Resistance
    2596 Diabetes Volume 66, October 2017 Adipocyte-SpecificDeficiency of De Novo Sphingolipid Biosynthesis Leads to Lipodystrophy and Insulin Resistance Su-Yeon Lee,1 Hui-Young Lee,2 Jae-Hwi Song,1 Goon-Tae Kim,1 Suwon Jeon,1 Yoo-Jeong Song,1 Jae Sung Lee,2 Jang-Ho Hur,2 Hyun Hee Oh,2 Shi-Young Park,2 Soon-Mi Shim,3 Hyun Joo Yoo,4 Byung Cheon Lee,5 Xian-Cheng Jiang,6 Cheol Soo Choi,2,7 and Tae-Sik Park1 Diabetes 2017;66:2596–2609 | https://doi.org/10.2337/db16-1232 Sphingolipids have been implicated in the etiology of as insulin resistance and cardiovascular diseases (1–3). chronic metabolic diseases. Here, we investigated whether White adipose tissue (WAT) stores lipids, and the spillover sphingolipid biosynthesis is associated with the develop- of excess fat from the WAT elevates plasma fatty acids (FA). ment of adipose tissues and metabolic diseases. SPTLC2, a As a result, ectopic lipids accumulated in peripheral organs subunit of serine palmitoyltransferase, was transcriptionally including liver cause steatosis and insulin resistance (4). upregulated in the adipose tissues of obese mice and In various reports of obese human and animal models, fi in differentiating adipocytes. Adipocyte-speci c SPTLC2- hepatosteatosis and insulin resistance have been found con- fi de cient (aSPTLC2 KO) mice had markedly reduced adipose comitantly, and altered fat distribution between adipose tissue mass. Fatty acids that were destined for the adi- tissues and peripheral organs has been suggested as a major pose tissue were instead shunted to liver and caused cause for development of metabolic dysfunction (5–7).
    [Show full text]
  • Perkinelmer Genomics to Request the Saliva Swab Collection Kit for Patients That Cannot Provide a Blood Sample As Whole Blood Is the Preferred Sample
    Autism and Intellectual Disability TRIO Panel Test Code TR002 Test Summary This test analyzes 2429 genes that have been associated with Autism and Intellectual Disability and/or disorders associated with Autism and Intellectual Disability with the analysis being performed as a TRIO Turn-Around-Time (TAT)* 3 - 5 weeks Acceptable Sample Types Whole Blood (EDTA) (Preferred sample type) DNA, Isolated Dried Blood Spots Saliva Acceptable Billing Types Self (patient) Payment Institutional Billing Commercial Insurance Indications for Testing Comprehensive test for patients with intellectual disability or global developmental delays (Moeschler et al 2014 PMID: 25157020). Comprehensive test for individuals with multiple congenital anomalies (Miller et al. 2010 PMID 20466091). Patients with autism/autism spectrum disorders (ASDs). Suspected autosomal recessive condition due to close familial relations Previously negative karyotyping and/or chromosomal microarray results. Test Description This panel analyzes 2429 genes that have been associated with Autism and ID and/or disorders associated with Autism and ID. Both sequencing and deletion/duplication (CNV) analysis will be performed on the coding regions of all genes included (unless otherwise marked). All analysis is performed utilizing Next Generation Sequencing (NGS) technology. CNV analysis is designed to detect the majority of deletions and duplications of three exons or greater in size. Smaller CNV events may also be detected and reported, but additional follow-up testing is recommended if a smaller CNV is suspected. All variants are classified according to ACMG guidelines. Condition Description Autism Spectrum Disorder (ASD) refers to a group of developmental disabilities that are typically associated with challenges of varying severity in the areas of social interaction, communication, and repetitive/restricted behaviors.
    [Show full text]
  • 0.16 Acat1 19.53 Gpat3 9.75 Acat2 0.04 Gpat4 Lpcat1 28.15 Agpat2
    Supplemental Table I. The gene expression of 27 acyltransferases in MOVAS-1 cells. Gene Name (pg)/18S(ng) Gene Name (pg)/18S(ng) Acat1 19.53 Gpat4 9.75 Acat2 0.04 Lclat1 1.05 Agpat1 34.31 Lpcat1 28.15 Agpat2 0.16 Lpcat2 0.22 Agpat3 71.11 Lpcat3 32.71 Agpat4 29.94 Lpcat4 9.49 Agpat5 3.30 Lpgat1 9.50 Awat1 N.D. Mboat1 35.55 Awat2 N.D. Mboat2 N.D. Dgat1 0.02 Mboat7 N.D. Dgat2 0.12 Mogat1 N.D. Gpat1 13.21 Mogat2 1.09 Gpat2 N.D. Sptlc1 0.12 Gpat3 0.16 The quantitative expression values of 27 acyltransferase were calculated using the absolute standard curve method of real-time qPCR with plasmid templates containing each full length target gene. Supplemental Table II. shRNA Clone IDs used for generating stable knockdown cells Gene Name Clone ID Acat1 V2LMM_34791 Acat2 V3LMM_423666 Agpat1 TRCN0000173860 Agpat2 V2LMM_64946 Agpat3 V3LMM_460834 Agpat4 V3LMM_446166 Agpat5 V3LMM_415929 Atf6 V3LMM_459160 Dgat1 TRCN0000124789 Dgat2 TRCN0000125476 Gpat1 TRCN0000012156 Gpat3 TRCN0000099285 Gpat4 V3LMM_414952 Ire1 V3LMM_425499 Lipin2 TRCN0000098248 Lpcat1 TRCN0000183242 Lpcat2 V3LMM_508093 Lpcat3 V3LMM_511114 Lpcat4 V3LMM_451294 Lpgat1 TRCN0000125609 Mboat1 V3LMM_510216 Mogat2 TRCN0000018442 Scd2 V3LMM_516055 Sptlc1 TRCN0000103400 MOVAS-1 cells were infected with lentiviruses expressing Acat (1 or 2), Agpat (1, 2, 3, 4, or 5), Atf6, Dgat(1 or 2), Gpat (1, 3 or 4), Ire1, Lipin2, Lpcat (1, 2, 3, or 4), Lpgat1, Mboat1, Mogat2, Scd2 or Sptlc1 shRNA and selected with puromycin for 7 days. Each mRNA level was measured by real-time qPCR. Changes in gene expression are reported as ratios relative to the control empty shRNA.
    [Show full text]